UNSPSC 51401535: Nortetrazepam

This classification denotes a benzodiazepine with the molecular formula C15H15ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PWL441R6EQ, chemically known as 7-chloro-5-(1-cyclohexen-1-yl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as nortetrazepam, which bears US NIH Compound Identifier 166581. European Medicines Agency schedules Nortetrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09379MIG.

UNSPSC 51401535 Nortetrazepam is a Commodity code that maps poorly to the recent state and local solicitations tagged under it. The three opportunities on record—a Seminole County naloxone and drug deactivation procurement, a Texas HHS pharmacy benefit RFI, and a Minnesota multistate pharmaceutical cooperative RFP—involve naloxone, generic pharmaceuticals, and OTC products, not nortetrazepam specifically. The code shows minimal relevant recent activity; state and local buyers appear to be sourcing benzodiazepines and controlled substances through broader pharmaceutical procurement vehicles rather than single-drug commodity buys. Issuing bodies include county health departments (Seminole County), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP), each pursuing different pharmacy-supply models—direct purchase, direct-to-manufacturer programs, and wholesaler-distributed generic sourcing.

Geographic activity centers on Florida, Texas, and Minnesota. The most concrete recent opportunity is Seminole County's IFB60459723LAS (posted June 30, 2026, response due July 26, 2023), an IFB for naloxone and drug deactivation systems with quarterly deliveries to the county community health building and a two-year initial term plus one-year renewal option. The Minnesota MMCAP RFP (S1070000015802, posted January 20, 2026, due March 26, 2026) establishes multistate contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, effective July 1, 2026, with price competitiveness weighted at 75 percent of the evaluation. The Texas HHS RFI (HHS0017013, posted April 3, 2026) is exploratory market intelligence on direct-to-manufacturer prescription models for self-insured plans rather than a procurement order. Nortetrazepam as tagged does not align with the work actually being bought; interest in this code should be qualified by awareness that the recent record reflects general pharmaceutical sourcing, not benzodiazepine-specific demand signals.